- Home
- NVAX vs USA Comparison
NVAX vs USA Comparison
Compare NVAX & USA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVAX
- USA
- Stock Information
- Founded
- NVAX 1987
- USA 1986
- Country
- NVAX United States
- USA United States
- Employees
- NVAX N/A
- USA N/A
- Industry
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- USA Finance Companies
- Sector
- NVAX Health Care
- USA Finance
- Exchange
- NVAX Nasdaq
- USA Nasdaq
- Market Cap
- NVAX 1.3B
- USA N/A
- IPO Year
- NVAX 1995
- USA N/A
- Fundamental
- Price
- NVAX $7.12
- USA $6.92
- Analyst Decision
- NVAX Buy
- USA
- Analyst Count
- NVAX 5
- USA 0
- Target Price
- NVAX $16.60
- USA N/A
- AVG Volume (30 Days)
- NVAX 5.1M
- USA 880.5K
- Earning Date
- NVAX 08-07-2025
- USA 01-01-0001
- Dividend Yield
- NVAX N/A
- USA 9.66%
- EPS Growth
- NVAX N/A
- USA N/A
- EPS
- NVAX 2.97
- USA N/A
- Revenue
- NVAX $1,254,962,000.00
- USA N/A
- Revenue This Year
- NVAX $56.85
- USA N/A
- Revenue Next Year
- NVAX N/A
- USA N/A
- P/E Ratio
- NVAX $2.37
- USA N/A
- Revenue Growth
- NVAX 25.92
- USA N/A
- 52 Week Low
- NVAX $5.01
- USA $5.62
- 52 Week High
- NVAX $17.81
- USA $7.09
- Technical
- Relative Strength Index (RSI)
- NVAX 57.25
- USA 63.95
- Support Level
- NVAX $6.54
- USA $6.84
- Resistance Level
- NVAX $6.90
- USA $6.96
- Average True Range (ATR)
- NVAX 0.29
- USA 0.07
- MACD
- NVAX 0.06
- USA 0.02
- Stochastic Oscillator
- NVAX 92.52
- USA 90.00
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.